SBI Okasan Asset Management Co.Ltd. Takes Position in IQVIA Holdings Inc. $IQV

SBI Okasan Asset Management Co.Ltd. acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,500 shares of the medical research company’s stock, valued at approximately $2,839,000. IQVIA makes up 0.2% of SBI Okasan Asset Management Co.Ltd.’s investment portfolio, making the stock its 29th largest holding.

A number of other institutional investors have also recently made changes to their positions in the company. Eubel Brady & Suttman Asset Management Inc. bought a new stake in IQVIA in the third quarter worth about $14,278,000. Eagle Rock Investment Company LLC lifted its stake in IQVIA by 33.6% in the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after purchasing an additional 11,657 shares during the last quarter. OPTIMAS CAPITAL Ltd bought a new stake in IQVIA in the third quarter worth about $4,008,000. EDENTREE ASSET MANAGEMENT Ltd bought a new stake in IQVIA in the third quarter worth about $7,368,000. Finally, AMG National Trust Bank bought a new stake in IQVIA in the third quarter worth about $3,713,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Truist Financial decreased their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Citigroup decreased their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Mizuho set a $215.00 target price on shares of IQVIA in a research report on Monday, February 23rd. Finally, Evercore reaffirmed an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Buy” and an average target price of $225.69.

IQVIA Stock Performance

Shares of IQV stock opened at $180.92 on Friday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market cap of $30.20 billion, a PE ratio of 22.42, a PEG ratio of 1.58 and a beta of 1.18. IQVIA Holdings Inc. has a 12-month low of $136.41 and a 12-month high of $247.04. The business’s fifty day simple moving average is $170.04 and its 200-day simple moving average is $196.28.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.